argenx to Present at Upcoming Investor Conferences

Rhea-AI Summary

argenx (Euronext & Nasdaq: ARGX), a global immunology company, has announced its management team's participation in three major healthcare conferences this December. The schedule includes presentations at Citi's 2024 Global Healthcare Conference in Miami (December 3), the 7th Annual Evercore I&I HealthCONx Conference in Coral Gables (December 4), and Piper Sandler's 35th Annual Healthcare Conference in New York (December 5). All presentations will be fireside chats, with additional information available on the company's investor relations website.

News Market Reaction – ARGX

+0.25%

+0.25% Session move

In the trading session that priced this news, ARGX gained 0.25%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

November 26, 2024

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December.

• Citi’s 2024 Global Healthcare Conference. Fireside chat on Tuesday, December 3 at 1:45 p.m. ET in Miami, FL.
  
  
• 7^th Annual Evercore I&I HealthCONx Conference. Fireside chat on Wednesday, December 4 at 1:45 p.m. ET in Coral Gables, FL.
  
  
• Piper Sandler’s 35^th Annual Healthcare Conference. Fireside chat on Thursday, December 5 at 9:00 a.m. ET in New York, NY.
  
  

Additional information regarding these events will be available on the Investors section of the argenx website at argenx.com/investors.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.

For further information, please contact:

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy (US)
aroy@argenx.com

Lynn Elton (EU)
lelton@argenx.com

FAQ

What investor conferences will argenx (ARGX) attend in December 2024?

argenx will attend three conferences: Citi's Global Healthcare Conference (Dec 3), Evercore I&I HealthCONx Conference (Dec 4), and Piper Sandler's Healthcare Conference (Dec 5).

When is argenx (ARGX) presenting at Citi's 2024 Global Healthcare Conference?

argenx will present at Citi's 2024 Global Healthcare Conference on Tuesday, December 3 at 1:45 p.m. ET in Miami, FL.

Where can investors find additional information about argenx's (ARGX) conference presentations?

Additional information about argenx's conference presentations can be found on the Investors section of the argenx website at argenx.com/investors.